Special Information

Influenza A virus vaccine (H1N1)

Available as monovalent, inactivated influenza A virus vaccine (H1N1) for IM injection. Indicated for active immunization against influenza caused by pandemic (H1N1) 2009 virus. Stimulates active immunity to influenza virus infection by inducing production of specific antibodies.

  • Dosing
  • Interactions
  • Contraindications
  • Precautions

IM injection: 0.5 mL IM in deltoid muscle of upper arm (1 dose)


IM injection (Sanofi Pasteur and CSL Limited vaccines)
6-35 months: 0.25 mL IM; administer 2 injections approximately 4 wk apart
3-9 years: 0.5 mL IM; administer 2 injections approximately 4 wk apart
10-17 years: Administer as in adults
IM injection (Novartis vaccine)

Do not mix with other vaccine in same syringe or vial; immunosuppressive therapies may decrease immune response to vaccine
Hypersensitivity to eggs or chicken protein, neomycin, or polymyxin; life-threatening reaction to previous influenza vaccination


C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus


Guillain-Barré syndrome has occurred within 6 wk of previous influenza vaccination; immunocompromised persons may have a diminished immune response to vaccine; common injection site adverse effects (≥10%) include tenderness, pain, redness, and swelling; common systemic adverse effects (≥10%) include headache, malaise, and myalgia;   multi dose vial contains thimerosal, a mercury derivative